Author page: Femtech Insider

Roundup: Clinical Trial Updates from May Health, AOA Dx & Hera Biotech

May Health Completes Treatment of Five Participants in U.S. Feasibility Study of its Ovarian Rebalancing Treatment for PCOS-related Infertility May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), announced that it has completed treatment of the first five participants enrolled in a U.S. feasibility study of its investigational Ovarian Rebalancing™ treatment,…

What’s New in Femtech This Week? (Jan 12, 2023)

Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is the latest edition. If you’re interested in subscribing, you can do so at the bottom of this page. This Week’s Highlights Employee benefits platform Peppy adds $45M in Series B funding to continue its expansion in the US. Hybrid care company Herself Health raises $7M in funding to transform primary care for…

Employee Benefits Platform Peppy Adds $45M in Series B Funding to Continue Its Expansion in the US

Peppy, the London-based digital health startup focused on women’s health has raised $45M in Series B funding led by Albion VC. Other investors in the round include Kathaka, MTech Capital Simplyhealth, Sony Innovation Fund as well as existing investors Felix Capital, Hambro Perks, Outward VC, and Seedcamp. The fresh funds will be used to fund the companies expansion to the US market.…

CirrusMD Launches Abortion Referral Services

CirrusMD, a leading provider of on-demand virtual care, today announced it will provide abortion referral services for pregnant people who need trusted, quality abortion care. This is the most recent initiative supporting the CirrusMD mission of expanding access to high quality care for all people, especially those who feel underserved by the US healthcare system. This announcement comes at a time of…

Femasys’ FemCath, an Intrauterine Device for Selective Tubal Evaluation, Is Now Commercially Available

Femasys, a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, has announced that its product, FemCath, the first FDA-cleared intrauterine catheter for selective tubal evaluation, is now commercially available. FemCath is used in conjunction with Femasys’ FemVue device for an ultrasound-based diagnostic test as part of…

Posterity Health and Path Fertility Release a New IUI Assessment to Predict Intrauterine Insemination Success

Posterity Health, the only virtual male fertility clinic that offers personalized care, educational resources, and effective treatments to address male fertility has joined forces with Path Fertility, the creators of SpermQT, an epigenetic sperm quality test that can predict fertility outcomes not detected in a standard semen analysis. Together the companies now offer a new comprehensive IUI Assessment that evaluates multiple semen…

Hybrid Care Company Herself Health Raises $7M in Funding to Transform Primary Care for Women Over 65

Herself Health, a new healthcare technology company designed to deliver advanced primary care to women over 65, announced today its first clinic opening. The company received $7M in Seed round funding led by founding partner Juxtapose. Herself Health, co-built by Juxtapose and CEO Kristen Helton, will also welcome former President and CEO of WW (formerly Weight Watchers) and current partner at the Consello…

Organon Invests $8M in Claria Medical to Support the Development of an Investigational Medical Device for Minimally Invasive Hysterectomy

Women’s health focused pharma company Organon has made a $8M strategic investment in Claria Medical, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. The agreement also grants Organon the option to acquire Claria Medical in the future. “Hysterectomy is one of the most commonly performed surgeries for women, which is why it is critical…